• Felicia Yarde, Marlies Voorhuis, Madeleine Dólleman, Erik A H Knauff, Marinus J C Eijkemans, and Frank J M Broekmans.
• Department of Reproductive Medicine and Gynaecology, University Medical Center Utrecht, Utrecht, The Netherlands. F.Yarde@umcutrecht.nl
• Fertil. Steril. 2013 Sep 1; 100 (3): 831-8.

ObjectiveTo investigate the role of serum antimüllerian hormone (AMH) as a predictor of live birth and reproductive stage in subfertile women with elevated basal FSH levels.DesignA prospective observational cohort study conducted between February 2005 and June 2009.SettingTertiary fertility center.Patient(S)Subfertile women with [1] a regular menstrual cycle (mean cycle length 25-35 days); [2] basal FSH concentrations ≥12.3 IU/L; and [3] younger than 40 years (n = 96).Intervention(S)None.Main Outcome Measure(S)Live birth and reproductive stage according to the Stages of Reproductive Aging Workshop.Result(S)A cumulative live birth rate of 63.5% was observed during a median follow-up of 3.3 years (n = 85). The AMH level was significantly associated with live birth. There was evidence of a nonlinear prediction pattern, with an increase in chances of live birth until an AMH level of 1 μg/L. Other ovarian reserve tests and chronological age appeared of limited value in predicting live birth. In addition, AMH was significantly associated with the timing of reproductive stages (n = 68) (i.e., the occurrence of menopausal transition or menopause during follow-up).Conclusion(S)The present findings suggest applicability of AMH determination as a marker for actual fertility in subfertile women with elevated basal FSH levels.Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

30 keywords...

hide…